OvaScience Inc (OVAS)

1.52
NASDAQ : Health Care
Prev Close 1.52
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.25 / 8.98
Avg Volume 453.40K
Exchange NASDAQ
Shares Outstanding 35.66M
Market Cap 54.21M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OvaScience Completes Enrollment Of 70 Patients In OvaPrime Clinical Study In Women With Primary Ovarian Insufficiency Or Poor Ovarian Response

OvaScience SM Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced it has completed enrollment of 70 patients in its ongoing...

OvaScience Reports First Quarter 2017 Financial Results

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the first...

OvaScience To Host First Quarter 2017 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In OvaScience, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

OvaScience Stock Sees Short Interest Expand By 29.7%

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 1,457,802 share increase in total short interest for OvaScience Inc. , to 6,361,911, an increase of 29.73% since 03/31/2017.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In OvaScience, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

OvaScience Reports Fourth Quarter And Year-End 2016 Financial Results

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the fourth...

OvaScience To Present At Upcoming Investor Conferences In March

OvaScience¿ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Christophe Couturier, Chief Financial Officer of...

OvaScience To Host Fourth Quarter And Fiscal Year 2016 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Newman Ferrara LLP Announces Corporate Governance Investigation Of OvaScience, Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OvaScience, Inc.

OvaScience Stock Sees Short Interest Move 10.4% Higher

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 492,925 share increase in total short interest for OvaScience Inc. , to 5,232,302, an increase of 10.40% since 01/13/2017.

OvaScience To Present At The 35th Annual J.P. Morgan Healthcare Conference

OvaScience To Present At The 35th Annual J.P. Morgan Healthcare Conference

OvaScience¿ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Michelle Dipp, M.

OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced the grant of inducement awards to purchase an aggregate of 356,000...

OvaScience Announces Business Update

OvaScience Announces Business Update

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced a business update.

First Week of OVAS February 2017 Options Trading

First Week of OVAS February 2017 Options Trading

Investors in OvaScience Inc. saw new options become available this week, for the February 2017 expiration.

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

OvaScience Reports Third Quarter 2016 Financial Results

OvaScience Reports Third Quarter 2016 Financial Results

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new female infertility treatments, today reported its third quarter 2016 financial results and...

OvaScience To Present At The 25th Annual Credit Suisse Healthcare Conference

OvaScience To Present At The 25th Annual Credit Suisse Healthcare Conference

OvaScience¿ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald Stock, Ph.

OvaScience To Host Third Quarter 2016 Financial Results Conference Call

OvaScience To Host Third Quarter 2016 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?

OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement awards to its newly appointed Chief...